Exclusive: Sanofi, Astellas venture arms add cash to Avilar’s ‘ATAC’ mission

Endpoints News: The venture arms of Sanofi and Astellas have grown their investment in Avilar Therapeutics to help steer the biotech through a niche of the growing protein degradation field.